Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) was the target of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 228,400 shares, adecreaseof26.4% from the July 15th total of 310,500 shares. Currently,0.6% of the shares of the stock are sold short. Based on an average trading volume of 462,000 shares, the short-interest ratio is currently 0.5 days. Based on an average trading volume of 462,000 shares, the short-interest ratio is currently 0.5 days. Currently,0.6% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Jones Trading cut Theratechnologies from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 3rd. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.

Theratechnologies Stock Up 0.3%

Shares of THTX opened at $3.26 on Friday. The stock has a market capitalization of $149.89 million, a P/E ratio of -17.16 and a beta of 0.52. The firm has a fifty day simple moving average of $2.98 and a two-hundred day simple moving average of $2.41. Theratechnologies has a twelve month low of $1.12 and a twelve month high of $3.26.

Theratechnologies (NASDAQ:THTX) last issued its quarterly earnings data on Wednesday, July 9th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The business had revenue of $17,729 billion for the quarter, compared to analyst estimates of $24.30 million. Sell-side analysts expect that Theratechnologies will post 0.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in THTX. Rangeley Capital LLC purchased a new position in shares of Theratechnologies in the second quarter worth approximately $118,000. BNP Paribas Financial Markets raised its position in shares of Theratechnologies by 86.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 55,459 shares of the company’s stock valued at $131,000 after purchasing an additional 25,686 shares during the period. Stonepine Capital Management LLC raised its position in shares of Theratechnologies by 632.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 189,051 shares of the company’s stock valued at $446,000 after purchasing an additional 163,226 shares during the period. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Theratechnologies in the second quarter worth $313,000. Finally, TD Waterhouse Canada Inc. lifted its holdings in shares of Theratechnologies by 63.4% in the second quarter. TD Waterhouse Canada Inc. now owns 18,038 shares of the company’s stock worth $41,000 after buying an additional 7,000 shares in the last quarter.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.